<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">27783196</PMID>
<DateCompleted>
<Year>2017</Year>
<Month>07</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>12</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1573-7403</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>20</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2017</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>Pituitary</Title>
<ISOAbbreviation>Pituitary</ISOAbbreviation>
</Journal>
<ArticleTitle>Management of prolactinomas: a survey of physicians from the Middle East and North Africa.</ArticleTitle>
<Pagination>
<MedlinePgn>231-240</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s11102-016-0767-5</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Prolactinomas are the commonest functional tumors of the pituitary gland. There are still controversies regarding medical therapy in specific clinical situations. Patients may be managed by different specialists in the Middle East and North Africa (MENA) region and no data exist on patterns of clinical management.</AbstractText>
<AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To ascertain the diagnostic and therapeutic approaches to prolactinomas among relevant professionals from the MENA region.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">An online survey of a large sample of physicians was conducted. The questionnaire covered various aspects of diagnosis and treatment of prolactinomas. 468 respondents were included; 36 % were endocrinologists; 49 % worked in public facilities and 81 % graduated more than 10 years. 40 and 30 % would have seen 1-5 and more than 5 suspected or confirmed prolactinomas over a 6 months period, respectively.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Regarding the diagnosis, 30 % of the respondents considered that prolactin levels &lt;100 ng/ml exclude the presence of a prolactinoma. 21 % of respondents considered prolactin levels &gt;250 ng/ml compatible with macroprolactinomas only, whereas others accepted this to be compatible also with microprolactinomas, macroprolactinaemia and drug-induced hyperprolactinemia (50, 42 and 36 % respectively). 71 % of respondents favored the screening for macroprolactin in asymptomatic individuals with hyperprolactinemia. Regarding the treatment, 84 % of respondents would treat microprolactinomas even in the absence of symptoms whereas 72 % of the respondents would treat microprolactinomas only if symptoms exist. 60 and 49 % of the respondents chose cabergoline as the drug of choice to treat macroprolactinomas and microprolactinomas respectively. Similar proportions had no preference of either cabergoline or bromocriptine as the best treatment for macroprolactinoma (27 %) and microprolactinomas (32 %). 46 and 75 % of respondents favored treatment withdrawal 2-3 years after prolactin normalization in patients with macroprolactinomas and microprolactinomas, respectively whereas 10 % of respondents withdraw treatment after menopause in either case. 94 % of respondents considered medical therapy as the primary treatment for microprolactinomas. In case of pregnancy, 49 % considered bromocriptine as the drug of choice for women who wish to become pregnant. 65 and 38 % of respondents advocated discontinuation of treatment with dopamine agonists in patients with microprolactinomas and macroprolactinomas, respectively. Finally, 48 % would allow breast-feeding without restriction, 28 % would restrict it to patients with microprolactinomas and 25 % would not recommend it for women with prolactinomas.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This is the first study of the clinical management of prolactinomas in the MENA region. Some of the practices are not in line with the latest Endocrine and Pituitary Societies guidelines. These warrant further discussions of contemporary guidelines in regional forums.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Beshyah</LastName>
<ForeName>Salem A</ForeName>
<Initials>SA</Initials>
<AffiliationInfo>
<Affiliation>Center for Diabetes and Endocrinology, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates. beshyah@yahoo.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sherif</LastName>
<ForeName>Ibrahim H</ForeName>
<Initials>IH</Initials>
<AffiliationInfo>
<Affiliation>Al Afia Clinic, Tripoli, Libya.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chentli</LastName>
<ForeName>Farida</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Bab El Oued Hospital, Algiers, Algeria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hamrahian</LastName>
<ForeName>Amir</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Khalil</LastName>
<ForeName>Aly B</ForeName>
<Initials>AB</Initials>
<AffiliationInfo>
<Affiliation>Imperial College London Diabetes Center, Abu Dhabi, United Arab Emirates.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Raef</LastName>
<ForeName>Hussein</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>El-Fikki</LastName>
<ForeName>Mohamed</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>University of Alexandria, Alexandria, Egypt.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jambart</LastName>
<ForeName>Selim</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Saint-Joseph University, Beirut, Lebanon.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Pituitary</MedlineTA>
<NlmUniqueID>9814578</NlmUniqueID>
<ISSNLinking>1386-341X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004873">Ergolines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9002-62-4</RegistryNumber>
<NameOfSubstance UI="D011388">Prolactin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>LL60K9J05T</RegistryNumber>
<NameOfSubstance UI="D000077465">Cabergoline</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000352">Africa, Northern</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000077465">Cabergoline</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018491">Dopamine Agonists</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004873">Ergolines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008877">Middle East</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010820">Physicians</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010911">Pituitary Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011388">Prolactin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015175">Prolactinoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011795">Surveys and Questionnaires</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Hyperprolactinemia</Keyword>
<Keyword MajorTopicYN="N">MENA region</Keyword>
<Keyword MajorTopicYN="N">Pituitary tumors</Keyword>
<Keyword MajorTopicYN="N">Prolactin</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2016</Year>
<Month>10</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2017</Year>
<Month>7</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2016</Year>
<Month>10</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">27783196</ArticleId>
<ArticleId IdType="doi">10.1007/s11102-016-0767-5</ArticleId>
<ArticleId IdType="pii">10.1007/s11102-016-0767-5</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Pituitary. 2010 Sep;13(3):199-206</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20107911</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Endocrinol Metab Clin North Am. 2015 Mar;44(1):89-97</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25732645</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Endocrinol (Oxf). 2005 Jul;63(1):26-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15963057</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Endocrinol Metab Clin North Am. 2015 Mar;44(1):71-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25732643</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Endocrinol. 2008 Jan;158(1):11-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18166812</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 1994 Oct 6;331(14):904-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7915824</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>BMJ. 2014 Sep 10;349:g5390</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25208537</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Minerva Endocrinol. 2016 Sep;41(3):316-23</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26399371</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Endocr Pract. 2015 Dec;21(12):1427-35</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26642103</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Endocrinol (Oxf). 2006 Aug;65(2):265-73</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16886971</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Endocrinol (Paris). 2016 Jun;77(2):128-34</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">27130071</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Pituitary. 2015 Oct;18(5):745-51</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25500765</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2010 Apr 1;362(13):1219-26</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20357284</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 1989 Feb;68(2):412-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2918052</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 2011 Feb;96(2):273-88</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21296991</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 2009 Jul;94(7):2428-36</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19336508</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Endocrinol. 2014 Jun;170(6):R213-27</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24536090</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Endocrinol (Paris). 2015 Feb;76(1):43-58</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25556152</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Endocrine. 2015 Feb;48(1):79-82</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24888765</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Pituitary. 2011 Sep;14(3):222-30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21170594</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Endocrine. 2015 Feb;48(1):76-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25112228</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 1999 Jul;84(7):2518-22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10404830</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>